TB-500 dosing & administration
A powerful fragment of thymosin beta-4 that acts like your body's repair signal—speeding up healing of muscles, tendons, and tissues by promoting cell migration and new blood vessel growth right where you need it most.
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Dosing
How much do I take?
Subcutaneous: A small injection into the fatty layer just under the skin — the same way insulin is given.
Bioavailability High — most of the dose reaches your bloodstream, just more gradually than an IV.
2 documented dose levels — separate regimens, not a titration schedule
Timing
Best time to take
Morning or evening—timing doesn't significantly affect TB-500's effectiveness. What matters most is consistency. Pick a schedule that works for your lifestyle and stick with it.
With food?
TB-500 can be injected regardless of food timing. It doesn't seem to affect absorption either way, so fit it into whatever routine works for you.
If stacking
TB-500 pairs exceptionally well with BPC-157—they're often called the 'healing stack' because they work through different but complementary mechanisms. Inject at different sites if using both. Space injections at least 15-30 minutes apart to track individual effects [6].
Adjusting your dose
Increase if
- You've completed 2+ weeks at starting dose with minimal healing progress
- Your injury is more severe than initially assessed
- You're recovering from surgery under professional guidance
- Your research protocol calls for loading phases
Decrease if
- You experience persistent headaches or fatigue beyond the first week
- Injection site reactions don't resolve within 48 hours
- You feel unusually tired or lethargic after each injection
- Any unexpected or uncomfortable side effects arise
Signs of right dose
- Noticeable improvement in injury flexibility or reduced stiffness
- Decreased pain at the injury site over 2-4 weeks
- Improved range of motion in affected areas
- Better exercise tolerance without aggravating the injury
Administration
How do I use it?
Reconstitution
What you need
Injection
Route
Subcutaneous injection (just under the skin)—the easiest and most common method. Some users prefer injecting near the injury site, though systemic administration works well too.
Best sites
Storage
Before reconstitution
Keep your TB-500 powder in the refrigerator (36-46°F / 2-8°C) for short-term storage or in the freezer (-4°F / -20°C) for long-term storage. Store in the original sealed vial away from light. Properly stored powder can remain stable for 2+ years when frozen.
After reconstitution
Once mixed with bacteriostatic water, refrigerate at 36-46°F (2-8°C). Never freeze the reconstituted solution—freezing destroys the peptide. Keep away from light and use within 28 days.
Signs of degradation — discard the vial
Sample daily schedule
Morning (or consistent time that works for you)
2-2.5 mg injection
Site: Rotate between belly, thigh, and near injury site
Inject twice weekly, spacing doses 3-4 days apart (e.g., Monday and Thursday). A typical loading phase uses 4-5 mg total per week for 4-6 weeks, followed by maintenance of 2-4 mg weekly if continued.
Safety
Is it safe?
Side effects
Commonly reported: Injection site redness, Mild fatigue or lethargy, Mild headache, Slight flushing
Less common: Head rush or lightheadedness, Temporary nausea
Stop and seek help if
- Any signs of allergic reaction—stop immediately and seek medical help
- Persistent headaches or fatigue that don't improve after the first week
- Significant injection site reactions that spread or don't heal
- Any side effect that feels serious or really concerns you
- Your injury has healed satisfactorily
- Your research protocol/cycle is complete
TB-500 is a research compound, not an FDA-approved medication. Never start, stop, or change your dosing without guidance from a qualified healthcare provider. This information is for educational purposes only—not medical advice.
Flagged pairings
- Blood thinners (warfarin, heparin) — May increase bleeding at injection sites. TB-500 promotes angiogenesis which could theoretically affect clotting. Monitor closely.
Published research
What the studies show
Goldstein AL, Hannappel E, Sosne G · 2012
This comprehensive review showed that thymosin beta-4 plays a vital role in tissue repair and regeneration. It protects cells from damage, reduces inflammation, promotes cell migration for healing, and helps form new blood vessels. The peptide also reduces scar formation by preventing fibroblasts from becoming scar-producing cells.
Goldstein AL, Kleinman HK · 2015
This update summarized decades of research showing TB4's effectiveness in directing stem cell maturation and tissue repair. Multiple clinical trials demonstrated benefits for eye injuries, skin wounds, and cardiac repair. The peptide shows potential for new applications including kidney and liver disease, spinal cord injury, and bone healing.
Xiong Y, Mahmood A, Meng Y, et al. · 2012
In brain injury models, thymosin beta-4 showed remarkable neuroprotective effects. It reduced cell death, decreased inflammation, promoted blood vessel formation, wound healing, and stem cell differentiation. The research provides scientific foundation for potential use in treating traumatic brain injury.
Kleinman HK, Kulik V, Goldstein AL · 2023
This study revealed TB4's powerful anti-scarring effects. It works by reducing inflammatory cell infiltration, lowering TGF-beta levels, and preventing fibroblasts from converting to myofibroblasts (scar-producing cells). The N-terminal fragment Ac-SDKP not only prevents fibrosis but can actually reverse existing scar tissue.
Zhao Y, Song J, Bi X, et al. · 2018
Researchers discovered that TB4 significantly improves blood vessel formation by enhancing the function of endothelial progenitor cells. It works through the VEGF pathway, which is crucial for delivering nutrients and oxygen to healing tissues. When transplanted into damaged heart tissue, TB4-treated cells showed much better blood vessel formation.
Peptide Dosing Protocols · 2026
World Anti-Doping Agency · 2026
Thymosin-β4 and its derivatives (e.g. TB-500) are listed under S2.2, growth factors and growth factor modulators, and are prohibited at all times — in and out of competition — as non-specified substances.
Sosne G, Ousler GW · 2015
A randomised, placebo-controlled Phase II trial in human subjects. The formulation was safe and well tolerated, with no significant adverse events reported and no subject withdrawing because of an adverse effect of the study formulation.
U.S. Food and Drug Administration (Mathew B, Mattingly A, Rupp T, Albuquerque E, Benedict A, Kneeream E, Kasim S) · 2026
Regulator evaluation dated 5/15/2026 of TB-500, described as the seven-amino-acid synthetic fragment of thymosin beta-4 (amino acids 17–23, N-acetylated). States that thymosin beta-4 and TB-500 are not the same substance. FDA found no clinical studies or human exposure data using TB-500 via any route, no clinical PK/PD studies in humans, no FAERS reports and no published case reports of adverse events; potential safety risks in humans are unknown. As an injectable peptide (SC/IM), TB-500 may pose a significant risk for immunogenicity, potentially amplified by aggregation and peptide-related impurities; consequences of an immune response can range from antibody responses with no apparent clinical manifestations to life-threatening reactions.
Renke G, Chinellato L · 2026
Open-access review (Int J Mol Sci 2026). Describes TB-500 as the synthetic acetylated fragment corresponding to a key sequence of thymosin beta-4, and states the TB-500 fragment reproduces some of thymosin beta-4's effects, focusing on promoting new vessels and cell migration. In its safety section on thymosin beta-4 (the full protein), it reports no difference in adverse events vs placebo in ulcer studies and, with systemic use, rare reports of mild headaches.
Rahman OF, Lee SJ, Seeds WA · 2026
Open-access review (JAAOS Global Research & Reviews 2026). Describes TB-500 as a synthetic peptide fragment derived from thymosin beta-4 whose active segment promotes actin polymerization, progenitor cell recruitment and enhanced cellular migration; preclinical studies and veterinary use have suggested benefit in tendon and muscle repair with anti-inflammatory effects and proangiogenic activity. Lists distinct primary pathways for BPC-157 and TB-500. Notes a current lack of clinical trials.
Moiz A, O'Keefe EL, O'Keefe JH · 2026
Open-access review (Missouri Medicine 2026). Describes TB-500 as a synthetic peptide fragment replicating the active, acetylated region of thymosin beta-4, frequently co-administered with BPC-157 in unregulated fitness regimens to accelerate wound healing and muscular recovery. States no human safety or efficacy trials exist for elective cosmetic or athletic use, raises concern about unmonitored systemic use and occult tumour cells, and notes WADA prohibits TB-500 at all times.
Head to head
TB-500 compared
Studied for
Conditions TB-500 has been researched in
Want the full picture?
The complete TB-500 research profile: mechanism of action, clinical studies, effectiveness timeline, and FAQ.